Search Results - "Guerrero Zotano, A"

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials by Martín, M., Loibl, S., Hyslop, T., De la Haba-Rodríguez, J., Aktas, B., Cirrincione, C.T., Mehta, K., Barry, W.T., Morales, S., Carey, L.A., Garcia-Saenz, J.A., Partridge, A., Martinez-Jañez, N., Hahn, O., Winer, E., Guerrero-Zotano, A., Hudis, C., Casas, M., Rodriguez-Martin, C., Furlanetto, J., Carrasco, E., Dickler, M.N.

“…Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone…”
Get full text

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL by Martin, M., Zielinski, C., Ruiz-Borrego, M., Carrasco, E., Turner, N., Ciruelos, E.M., Muñoz, M., Bermejo, B., Margeli, M., Anton, A., Kahan, Z., Csöszi, T., Casas, M.I., Murillo, L., Morales, S., Alba, E., Gal-Yam, E., Guerrero-Zotano, A., Calvo, L., de la Haba-Rodriguez, J., Ramos, M., Alvarez, I., Garcia-Palomo, A., Huang Bartlett, C., Koehler, M., Caballero, R., Corsaro, M., Huang, X., Garcia-Sáenz, J.A., Chacón, J.I., Swift, C., Thallinger, C., Gil-Gil, M.

“…Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative,…”
Get full text

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial by Jhaveri, K., Eli, L.D., Wildiers, H., Hurvitz, S.A., Guerrero-Zotano, A., Unni, N., Brufsky, A., Park, H., Waisman, J., Yang, E.S., Spanggaard, I., Reid, S., Burkard, M.E., Vinayak, S., Prat, A., Arnedos, M., Bidard, F.-C., Loi, S., Crown, J., Bhave, M., Piha-Paul, S.A., Suga, J.M., Chia, S., Saura, C., Garcia-Saenz, J.Á., Gambardella, V., de Miguel, M.J., Gal-Yam, E.N., Rapael, A., Stemmer, S.M., Ma, C., Hanker, A.B., Ye, D., Goldman, J.W., Bose, R., Peterson, L., Bell, J.S.K., Frazier, A., DiPrimeo, D., Wong, A., Arteaga, C.L., Solit, D.B.

“…HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients…”
Get full text

Gestational breast cancer: distinctive molecular and clinico-epidemiological features by de la Haba-Rodríguez, J. R., Mínguez, P., Rojo, F., Martín, M., Alba, E., Servitja, S., Prat, A., Pérez-Fidalgo, J. A., Gavilá, J., Morales, C., Rodriguez-Lescure, A., Herrero, C., Peña-Enriquez, R, Herranz, J., Hernando, C., Hernández-Blanquisett, A., Guil-Luna, S., Martinez, MT, Blanch, S., Caballero, R., Martín, N., Pollán, M., Guerrero-Zotano, A., Bermejo, B.

“…Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6–15% of BC cases in…”
Get full text

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study by Gavilá, J., De La Haba, J., Bermejo, B., Rodríguez-Lescure, Á., Antón, A., Ciruelos, E., Brunet, J., Muñoz-Couselo, E., Santisteban, M., Rodríguez Sánchez, C. A., Santaballa, A., Sánchez Rovira, P., García Sáenz, J. Á., Ruiz-Borrego, M., Guerrero-Zotano, A. L., Huerta, M., Cotes-Sanchís, A., Lao Romera, J., Aguirre, E., Cortés, J., Llombart-Cussac, A.

“…Purpose To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients…”
Get full text

A prognostic index for locoregional recurrence after neoadjuvant chemotherapy by Herrero-Vicent, C, Guerrero-Zotano, A, Gavilá-Gregori, J, Hernández-Blanquisett, A, Sandiego-Contreras, S, Samper-Hiraldo, J M, Guillem-Porta, V, Ruiz-Simón, A

“…The appropriate selection criteria for breast-conserving surgery (BCS) or mastectomy after neoadjuvant chemotherapy (NAC) are poorly defined. The aim of this…”
Get full text

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study by Guerrero-Zotano, Á., Pérez-García, J.M., Ruiz-Borrego, M., Bermejo, B., Gil-Gil, M., de la Haba, J., Alba Conejo, E., Quiroga, V., Carañana, V., Urruticoechea, A., Morales, S., Bellet, M., Antón, A., Fernández-Abad, M., Sánchez-Rovira, P., Calabuig, L., Pérez-Escuredo, J., Sampayo-Cordero, M., Cortés, J., Llombart-Cussac, A.

“…The effect of the addition of cyclin-dependent kinases 4 and 6 inhibitors to endocrine therapy in terms of molecular downstaging remains undetermined…”
Get full text

35 High pathologic complete remission rate with liposome-encapsulated doxorubicin + paclitaxel + trastuzumab as primary treatment in HER-2 positive operable breast cancer: clinical experience by Gavila, J, Guerrero-Zotano, A, Climent, M.A, Blanch, S, Guillem, V, Camp, J, Tortajada, M.I, Gozalbo, F, Vidal, P, Ruiz, A

Get full text

Abstract PD7-10: Neoadjuvant trial with letrozole identifies PRR11 in 17q21-23 amplicon as a resistance mechanism to endocrine therapy in ER-positive breast cancer by Lee, K-M, Guerrero-Zotano, A, Formisano, L, Jansen, V, Gonzalez Ericsson, P, Arteaga, C

“…Approximately 20% of patients with early ER+ breast cancer (BC) treated with adjuvant antiestrogen therapy relapse with metastatic disease. Previously, we…”
Get full text

45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial by Chan, A., Moy, B., Mansi, J.L., Gnant, M.I., Barrios, C.H., Separovic, R., Guerrero-Zotano, A., Gore, I., Smith, J., Bryce, R.P., Xu, F., Wong, A., Martin, M., Holmes, F.A.

Get full text

Trajectories of alcohol consumption during life and the risk of developing breast cancer by Donat-Vargas, Carolina, Guerrero-Zotano, Ángel, Casas, Ana, Baena-Cañada, José Manuel, Lope, Virginia, Antolín, Silvia, Garcia-Saénz, José Ángel, Bermejo, Begoña, Muñoz, Montserrat, Ramos, Manuel, de Juan, Ana, Jara Sánchez, Carlos, Sánchez-Rovira, Pedro, Antón, Antonio, Brunet, Joan, Gavilá, Joaquín, Salvador, Javier, Arriola Arellano, Esperanza, Bezares, Susana, Fernández de Larrea-Baz, Nerea, Pérez-Gómez, Beatriz, Martín, Miguel, Pollán, Marina

“…Background Whether there are lifetime points of greater sensitivity to the deleterious effects of alcohol intake on the breasts remains inconclusive. Objective…”
Get full text

Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study by Donat-Vargas, Carolina, Guerrero-Zotano, Ángel, Lope, Virginia, Bermejo, Begoña, Casas, Ana, Baena-Cañada, José Manuel, Antolín, Silvia, Sánchez-Rovira, Pedro, Antón, Antonio, Garcia-Saénz, José Ángel, Ramos, Manuel, Muñoz, Montserrat, de Juan, Ana, Jara Sánchez, Carlos, Chacón, José Ignacio, Gil-Gil, Miguel, Andrés Conejero, Raquel, Llombart, Antonio, Bezares, Susana, Fernández de Larrea-Baz, Nerea, Pérez-Gómez, Beatriz, Martín, Miguel, Pollán, Marina

“…The Epi-GEICAM study comprises 1017 invasive BC cases matched with controls of similar age (49 ± 9 years) and residence. Diet and OO consumption were collected…”
Get full text

Relapsed hepatocellular carcinoma in transplanted liver. Local involvement and spread through the abdominal wall by Segura Huerta, A, Palomar Abad, L, Molina Saera, J, Guerrero Zotano, A, Pellín Ariño, L

Get full text

Incidence and predictors of ovarian function recovery (OFR) in exemestane patients with breast cancer (BC) with chemotherapy-induced amenorrhea (CIA) using two estradiol assays by Guerrero-Zotano, A., Gavila, J., Folkerd, E., Ortiz, B., Labrador, T., Martinez, F., Garcia, A., Climent, M. A., Guillem, V., Dowsett, M., Ruiz, A.

“…Abstract only…”
Get full text

Response to neoadjuvant chemotherapy and outcome based on breast cancer subtype by Guerrero-Zotano, A., Gavila, J., Climent, M. A., Juan, M. J., Guillem, V., Ruiz, A.

“…Abstract only e11516 Background: Gene expression profiling identifies several breast cancer subtypes with different chemosensitivity and outcome. We used…”
Get full text

Abstract P1-13-08: Extended adjuvant neratinib/fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ tumors following treatment with chemotherapy and anti-HER2 therapy by Sudhan, DR, Schwarz, LJ, Guerrero-Zotano, AL, Nixon, M, Formisano, L, Croessmann, S, Gonzalez Ericsson, PI, Sanders, ME, Balko, JM, Avogadri-Connors, F, Cutler, RE, Lalani, AS, Bryce, R, Auerbach, A, Arteaga, CL

“…Background: Neratinib is a potent, irreversible pan-HER tyrosine kinase inhibitor. The phase III trial ExteNET showed improved disease-free survival in…”
Get full text

Abstract PD5-02: Not presented by Guerrero-Zotano, AL, Stricker, TP, Hutchinson, KE, Stover, DG, Formisano, L, Lee, K-M, Schwarz, LJ, Giltnane, JM, Jansen, VM, Gavila, J, Perez-Fidalgo, A, Lluch, A, Llombart, A, Bayar, MA, Michiels, S, André, F, Arnedos, M, Ruiz, A, Arteaga, CL

“…This abstract was not presented at the symposium…”
Get full text

Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer by Formisano, L, Lu, Y, Jansen, VM, Bauer, JA, Hanker, A, Gonzalez Ericsson, P, Lee, K-M, Nixon, MJ, Guerrero-Zotano, AL, Schwarz, LJ, Sanders, M, Sudhan, D, Dugger, TC, Cruz, MR, Behdad, A, Cristofanilli, M, Bardia, A, O'Shaughnessy, J, Mayer, IA, Arteaga, CL

“…Background: CDK4/6 inhibitors have been approved in combination with endocrine therapy for treatment of ER+ metastatic breast cancer. The goal of this study…”
Get full text

Corroboration of polymorphisms in the aromatase (CYP19A1) gene with response to neoadjuvant therapy with letrozole in postmenopausal women with stages II-II ER/PgR-positive breast cancer by Lopez-Guerrero, J. A., Garcia-Casado, Z., Guerrero-Zotano, A. L., Calatrava, A., Ruiz-Sauri, A., Fernandez-Serra, A., Ruiz, A., Llombart-Bosch, A., Guillem-Porta, V., Llombart-Cussac, A.

“…Abstract only 602 Background: Aromatase (CYP19A1) is the main enzyme implicated in estrogen biosynthesis. Polymorphisms in CYP19A1 can affect both aromatase…”
Get full text

Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET) by Chan, A, Delaloge, S, Holmes, FA, Moy, B, Iwata, H, Harker, G, Masuda, N, Neskovic Konstantinovic, ZB, Petrakova, K, Guerrero Zotano, AL, Iannotti, N, Rodriguez, GI, Tassone, P, von Minckwitz, G, Ejlertsen, B, Chia, SKL, Mansi, J, Barrios, CH, Buyse, M, Wong, A, Bryce, R, Ye, Y, Martin, M

“…Background: Neratinib (Puma Biotechnology Inc), an irreversible pan-HER tyrosine kinase inhibitor, was evaluated in a phase 3 randomized, placebo-controlled,…”
Get full text